- Home
- AIM vs RVYL Comparison
AIM vs RVYL Comparison
Compare AIM & RVYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- RVYL
- Stock Information
- Founded
- AIM 1966
- RVYL 2007
- Country
- AIM United States
- RVYL United States
- Employees
- AIM N/A
- RVYL 99
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- RVYL Professional Services
- Sector
- AIM Health Care
- RVYL Consumer Discretionary
- Exchange
- AIM Nasdaq
- RVYL Nasdaq
- Market Cap
- AIM 9.8M
- RVYL 8.3M
- IPO Year
- AIM N/A
- RVYL N/A
- Fundamental
- Price
- AIM $0.14
- RVYL $0.99
- Analyst Decision
- AIM Strong Buy
- RVYL Hold
- Analyst Count
- AIM 2
- RVYL 1
- Target Price
- AIM $2.75
- RVYL N/A
- AVG Volume (30 Days)
- AIM 1.5M
- RVYL 92.3K
- Earning Date
- AIM 04-01-2025
- RVYL 03-25-2025
- Dividend Yield
- AIM N/A
- RVYL N/A
- EPS Growth
- AIM N/A
- RVYL N/A
- EPS
- AIM N/A
- RVYL N/A
- Revenue
- AIM $190,000.00
- RVYL $63,529,000.00
- Revenue This Year
- AIM N/A
- RVYL N/A
- Revenue Next Year
- AIM $1,693.10
- RVYL $48.92
- P/E Ratio
- AIM N/A
- RVYL N/A
- Revenue Growth
- AIM N/A
- RVYL 16.09
- 52 Week Low
- AIM $0.12
- RVYL $0.89
- 52 Week High
- AIM $0.62
- RVYL $4.65
- Technical
- Relative Strength Index (RSI)
- AIM 36.62
- RVYL 33.69
- Support Level
- AIM $0.12
- RVYL $1.14
- Resistance Level
- AIM $0.21
- RVYL $1.27
- Average True Range (ATR)
- AIM 0.02
- RVYL 0.09
- MACD
- AIM -0.00
- RVYL -0.02
- Stochastic Oscillator
- AIM 22.88
- RVYL 8.11
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.